U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H25NO4
Molecular Weight 391.4596
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLAVOXATE

SMILES

CC1=C(OC2=C(C=CC=C2C(=O)OCCN3CCCCC3)C1=O)C4=CC=CC=C4

InChI

InChIKey=SPIUTQOUKAMGCX-UHFFFAOYSA-N
InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3

HIDE SMILES / InChI

Molecular Formula C24H25NO4
Molecular Weight 391.4596
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Flavoxate is a drug, indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate is not indicated for definitive treatment, but is compatible with drugs used for the treatment of urinary tract infections. It was approved for use in the United States in 1970 and continues to be used. Drug acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, facilitating increased volume per void. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety, restlessness and in some instances agitation and delusions.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
FLAVOXATE HYDROCHLORIDE
Palliative
FLAVOXATE HYDROCHLORIDE
Palliative
FLAVOXATE HYDROCHLORIDE

Cmax

ValueDoseCo-administeredAnalytePopulation
4.61 mg/L
1.18 mg/kg single, intravenous
3-METHYLFLAVONE-8-CARBOXYLIC ACID plasma
Homo sapiens
14.4 μg/mL
200 mg single, oral
3-METHYLFLAVONE-8-CARBOXYLIC ACID plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
4.02 mg × h/L/(mg dose/kg)
2.55 mg/kg single, oral
3-METHYLFLAVONE-8-CARBOXYLIC ACID plasma
Homo sapiens
4.49 mg × h/L/(mg dose/kg)
1.18 mg/kg single, intravenous
3-METHYLFLAVONE-8-CARBOXYLIC ACID plasma
Homo sapiens
27.85 μg × h/mL
200 mg single, oral
3-METHYLFLAVONE-8-CARBOXYLIC ACID plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
40.1 min
1.18 mg/kg single, intravenous
3-METHYLFLAVONE-8-CARBOXYLIC ACID plasma
Homo sapiens
4.06 h
200 mg single, oral
3-METHYLFLAVONE-8-CARBOXYLIC ACID plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Adults and children over 12 years of age: one or two 100 mg tablets 3 or 4 times a day. With improvement of symptoms, the dose may be reduced. This drug cannot be recommended for infants and children under 12 years of age because safety and efficacy have not been demonstrated in this age group.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
3E74Y80MEY
Record Status Validated (UNII)
Record Version